Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. (SLDB) is a precision genetic medicine company whose news flow centers on the development of gene therapy candidates for rare neuromuscular and cardiac diseases. Company announcements highlight progress across multiple clinical programs, regulatory designations and collaborations related to its investigational therapies and platform technologies.
Investors and observers following SLDB news can expect updates on key clinical trials such as INSPIRE DUCHENNE and IMPACT DUCHENNE for SGT-003 in Duchenne muscular dystrophy, the FALCON Phase 1b trial of SGT-212 in Friedreich’s ataxia, and the ARTEMIS Phase 1b trial of SGT-501 for catecholaminergic polymorphic ventricular tachycardia. News items also describe interim clinical data, including safety, tolerability, biomarker changes and cardiac monitoring findings, as well as regulatory interactions and designations from agencies such as the U.S. Food and Drug Administration and U.K. authorities.
Solid Biosciences’ news releases additionally cover its proprietary AAV-SLB101 capsid platform, including data presentations at scientific meetings and licensing agreements with partners such as Andelyn Biosciences. Corporate updates, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in industry conferences like the J.P. Morgan Healthcare Conference also appear in the company’s news record.
This news page aggregates these disclosures so readers can review clinical milestones, regulatory developments, platform collaborations and corporate events related to Solid Biosciences and its SLDB stock over time.
Solid Biosciences (NASDAQ: SLDB) provided a 2026 outlook highlighting clinical progress across neuromuscular and cardiac programs and expanded access to its next‑generation capsid AAV‑SLB101.
Key points: 33 participants dosed with SGT‑003 in the Phase 1/2 INSPIRE Duchenne trial (safety cutoff 1/9/2026) with outpatient dosing enabled since Sept 2025; first participant enrolled in ex‑U.S. Phase 3 IMPACT Duchenne with dosing expected Q1 2026; first participant dosed in Phase 1b FALCON for SGT‑212 (FA); ARTEMIS sites activated for SGT‑501 (CPVT); FDA granted Orphan, Rare Pediatric Disease and Fast Track for SGT‑212; executed 50+ agreements for AAV‑SLB101.
Solid Biosciences (Nasdaq: SLDB) announced that the FDA granted Orphan Drug designation to SGT-212 for the treatment of Friedreich’s ataxia (FA). The company also holds Fast Track and Rare Pediatric Disease designations for SGT-212. The first participant has been dosed in FALCON, a Phase 1b first‑in‑human trial evaluating a novel dual‑route gene therapy (MRI‑guided intradentate nuclei infusion followed by IV) intended to restore frataxin. Initial clinical data are expected in H2 2026, subject to participant enrollment.
Solid Biosciences (NASDAQ: SLDB) announced dosing of the first participant in FALCON, its Phase 1b first‑in‑human trial of SGT‑212 for Friedreich’s ataxia on January 12, 2026. SGT‑212 uses a dual‑route approach: MRI‑guided stereotactic intradentate nuclei (IDN) infusion to the cerebellar dentate nuclei followed by an intravenous infusion, aiming to restore frataxin. Intra‑procedural MRI confirmed IDN targeting and coverage above company thresholds. The company expects preliminary safety insights in coming months and an initial data update in H2 2026, subject to participant enrollment.
Solid Biosciences (Nasdaq: SLDB) announced that President and CEO Bo Cumbo will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available on the company's Investors Events page, and a replay will be archived for 30 days.
This presentation provides investors and analysts access to management commentary and updates via webcast.
Solid Biosciences (Nasdaq: SLDB) announced on January 5, 2026 an inducement grant of 7,000 restricted stock units (RSUs) to a newly hired employee under the company’s 2024 Inducement Stock Incentive Plan. The RSUs vest in four equal annual installments on each one-year anniversary of the grant date through the fourth anniversary, subject to the employee’s continued service.
The grant was made as an inducement material to the employee’s acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) announced that Duchenne muscular dystrophy was added to the U.S. Recommended Uniform Screening Panel (RUSP) on Dec. 16, 2025, making it recommended for universal newborn screening.
Solid noted its long-term advocacy role, including participation on PPMD’s steering committee and a New York state pilot completed in 2021. The company said RUSP inclusion is expected to accelerate detection and enable earlier access to specialists, supportive interventions, and treatments.
Solid reiterated its focus on advancing its investigational gene therapy SGT-003 for Duchenne while celebrating earlier diagnosis and resource access for families.
Solid Biosciences (Nasdaq: SLDB) will present new data on its next-generation capsid AAV-SLB101 and cardiac gene therapy pipeline at the 22nd Global CardioVascular Clinical Trialists Forum, December 8-10, 2025, in Washington, D.C.
Chief Medical Officer Gabriel Brooks, M.D. will present two talks, a poster on AAV-SLB101 showing potent cardiac tropism and initial clinical safety, and join two panels; Nicolas Christoforou, Ph.D. will present preclinical work on a gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) and join a panel.
Presentations will be posted after the conference on the company’s Scientific Publications & Presentations page.
Solid Biosciences (Nasdaq: SLDB) announced on December 1, 2025 that it granted a total of 23,284 restricted stock units (RSUs) to two newly hired employees as inducement awards under the company’s 2024 Inducement Stock Incentive Plan.
The RSUs vest in four equal installments on each one-year anniversary of the grant date through the fourth anniversary, and vesting is subject to the employees' continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) announced on Dec 1, 2025 that the FDA granted Rare Pediatric Disease designation to SGT-212, its investigational dual-route gene therapy for Friedreich’s ataxia (FA).
SGT-212 delivers the full-length frataxin gene via both intradentate nucleus (IDN) and intravenous (IV) administration and has previously received Fast Track designation. The Rare Pediatric Disease designation makes SGT-212 potentially eligible for a pediatric priority review voucher (PRV), which can expedite future biologics review or be sold or transferred. The company said screening is underway for the FALCON Phase 1b first-in-human trial.
Solid Biosciences (Nasdaq: SLDB) announced a non-exclusive worldwide license and collaboration with Andelyn Biosciences for Solid’s proprietary next-generation capsid AAV-SLB101 on Nov 17, 2025. The agreement lets Andelyn offer AAV-SLB101 to gene therapy clients via its AAV Curator® Platform; financial terms were not disclosed. AAV-SLB101 has shown robust preclinical cardiac and skeletal muscle transduction and, as of the safety cutoff on Oct 31, 2025, was generally well tolerated in 23 pediatric participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial (NCT06138639). Solid reports >30 existing agreements/licenses for AAV-SLB101, and the deal aims to broaden access to the capsid for early-stage programs.
FAQ
What is the current stock price of Solid Bioscience (SLDB)?
What is the market cap of Solid Bioscience (SLDB)?
